Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Payables (2019 - 2025)

Historic Payables for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $6.3 million.

  • Benitec Biopharma's Payables rose 13797.56% to $6.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was $6.3 million, marking a year-over-year increase of 13797.56%. This contributed to the annual value of $4.2 million for FY2024, which is 2890.75% up from last year.
  • As of Q1 2025, Benitec Biopharma's Payables stood at $6.3 million, which was up 13797.56% from $2.4 million recorded in Q4 2024.
  • In the past 5 years, Benitec Biopharma's Payables ranged from a high of $6.3 million in Q1 2025 and a low of $880000.0 during Q2 2021
  • Its 5-year average for Payables is $2.8 million, with a median of $2.4 million in 2024.
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 44816.9% in 2021, then crashed by 5108.37% in 2024.
  • Quarter analysis of 5 years shows Benitec Biopharma's Payables stood at $1.9 million in 2021, then decreased by 5.96% to $1.8 million in 2022, then soared by 169.78% to $4.9 million in 2023, then crashed by 51.08% to $2.4 million in 2024, then soared by 158.96% to $6.3 million in 2025.
  • Its Payables stands at $6.3 million for Q1 2025, versus $2.4 million for Q4 2024 and $3.8 million for Q3 2024.